Design, Molecular Docking, Synthesis, Characterization and Preliminary Evaluation of Novel 1,3,4-Oxadiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
DOI:
https://doi.org/10.32947/ajps.v25i1.1132Keywords:
1,3,4-Oxadiazole, Colon Cancer, Molecular Docking, Schiff’s BasesAbstract
Novel 1,3,4-oxadiazole derivatives were designed, synthesized by reaction of semicarbazide hydrochloride with thiophene-2-carbaldehyde to form semicarbazone that undergo iodine-mediated cyclization to form 5-(thiophen-2-yl)-1,3,4-oxadiazol-2-amine which further reacted with different aldehydes to form Schiff base derivatives, and in-vitro tested for their cytotoxic activity. In a molecular docking study,
these chemicals were docked with the crystal structure of the cyclin-dependent kinase 2 protein (PDB code 2R3J) to assess their binding affinity. The recently developed analogues were validated, confirmed, and characterized using spectroscopic elemental analysis (FT-IR, 1H-NMR, and 13C-NMR). Furthermore, these compounds underwent physicochemical, drug-like, and toxicological predictions. The molecular docking investigation shows that 1,3,4-oxadiazole derivatives bind strongly to the CDK-2 protein's active binding site. From the studied molecules, compounds 5a and 5d had the highest binding, with docking scores of -10.654 and -10.169 kcal/mol. The reference ligand binding score was -9.919 kcal/mol. As assessed by their anti-proliferative effects, compounds 5a and 5d showed promising cytotoxicity against colon cancer in Caco-2 cells. The compounds had IC50 values of 43.16 and 60.8 μM at 24 hours, respectively, compared to the standard flavopiridol (59.2 μM). The findings of the cytotoxicity investigation and molecular docking analysis of these final derivatives (5a-5g) demonstrated a strong correlation, indicating the importance of a comprehensive pharmacological study to comprehend the anti-cancer mechanisms of these newly synthesized compounds fully.
References
1- Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. February 2015. Vol.14(48).
2- Al-Anazi M, Khairuddean M, O. Al-Najjar B, Murwih Alidmat M, Nur Syazni Nik Mohamed Kamal N, Muhamad M. Synthesis, anticancer activity and docking studies of pyrazoline and pyrimidine derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Arab J Chem. July 2022. Vol.15(7).
3- Shawky AM, Abdalla AN, Ibrahim NA, Abourehab MAS, Gouda AM. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Eur J Med Chem. June 2021. Vol.218.
4- Katsaounou K, Nicolaou E, Vogazianos P, Brown C, Stavrou M, Teloni S, et al. Colon Cancer: From Epidemiology to Prevention. Metabolites. May 2022. Vol. 12(6). P: 499.
5- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. June 1990. Vol. 61(5). P: 759-67.
6- Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. November 2017. Vol. 14(4). P: 348-362.
7- Chen J, Pang L, Wang W, Wang L, Zhang JZH, Zhu T. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations. J Biomol Struct Dyn. March 2020. Vol. 38(4) P: 985–96.
8- Phoujdar MS, Aland GR. Molecular docking study on 1H-(3,4d) pyrazolo-pyrimidines as cyclin dependant kinase (CDK2) inhibitors. Int J Curr Pharm Res. December 2016. Vol. 9(1). P: 94.
9- Peyressatre M, Prével C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers. January 2015. Vol. 7(1). P: 179-237.
10- Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. May 2017. Vol. 173. P: 83-105.
11- Kargbo RB. Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy. ACS Med Chem Lett. October 2022. Vol. 13(10). P: 1561–3.
12- Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q, Cai C. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. May 2021. Vol. 11(5). P: 1913-35.
13- Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers. September 2014. Vol. 6(3). P: 1769-92.
14- Kavitha S, Gnanavel S, Kannan K. Biological aspects of 1,3,4-oxadiazole derivatives. Asian J Pharm Clin Res. August 2014. Vol. 7(4). P: 11-20.
15- Boström J, Hogner A, Llinàs A, Wellner E, Plowright AT. Oxadiazoles in medicinal chemistry. J Med Chem. March 2012. Vol. 55(5). P: 1817–30.
16- Chortani S, Edziri H, Manachou M, Al-Ghamdi YO, Almalki SG, Alqurashi YE, et al. Novel 1,3,4-oxadiazole linked benzopyrimidinones conjugates: Synthesis, DFT study and antimicrobial evaluation. J Mol Struct. October 2020. Vol. 1217.
17- Jwaid MM, Ali KF, Abd-alwahab MH. Synthesis, Antibacterial study and ADME Evaluation of Novel Isonicotinoyl Hydrazide Derivative Containing 1,3,4-Oxadiazole Moiety. Al Mustansiriyah Journal of Pharmaceutical Sciences. December 2020. Vol. 20(4). P: 113-21.
18- Bajaj S, Kumar MS, Tinwala H, YC M. Design, synthesis, modelling studies and biological evaluation of 1,3,4-oxadiazole derivatives as potent anticancer agents targeting thymidine phosphorylase enzyme. Bioorg Chem. June 2021. Vol. 111.
19- Alam MM, Almalki ASA, Neamatallah T, Ali NM, Malebari AM, Nazreen S. Synthesis of new 1, 3, 4-oxadiazole-incorporated 1, 2, 3-triazole moieties as potential anticancer agents targeting thymidylate synthase and their docking studies. Pharmaceuticals. November 2020. Vol. 13(11). P: 1–15.
20- Küçükoğlu K, Acar Çevik U, Nadaroglu H, Celik I, Işık A, Bostancı HE, et al. Design, synthesis and molecular docking studies of novel benzimidazole-1,3,4-oxadiazole hybrids for their carbonic anhydrase inhibitory and antioxidant effects. Med Chem Res. October 2022. Vol. 31(10). P: 1771–82.
21- Singh RB, Das N, Singh GK, Singh SK, Zaman K. Synthesis and pharmacological evaluation of 3-[5-(aryl-[1,3,4]oxadiazole-2-yl]-piperidine derivatives as anticonvulsant and antidepressant agents. Arab J Chem. May 2020. Vol. 13(5). P: 5299–311.
22- Kashid BB, Salunkhe PH, Dongare BB, More KR, Khedkar VM, Ghanwat AA. Synthesis of novel of 2, 5-disubstituted 1, 3, 4- oxadiazole derivatives and their in vitro anti-inflammatory, anti-oxidant evaluation, and molecular docking study. Bioorg Med Chem Lett. June 2020. Vol. 30(12).
23- Kumar D, Kumar RR, Pathania S, Singh PK, Kalra S, Kumar B. Investigation of indole functionalized pyrazoles and oxadiazoles as anti-inflammatory agents: Synthesis, in-vivo, in-vitro and in-silico analysis. Bioorg Chem. September 2021. Vol. 114.
24- Omran SM, Abd Razik BM, Mahdi MF. Density functional theory and molecular modeling studies of new 4-(Furan-2-yl) thiazol-2-amine derivatives as cyclooxygenase inhibitors. Egypt J Chem. September 2021. Vol. 64(9). P: 4833–41.
25- Ali YS, Mahdi MF, Abd Razik BM. In silico evaluation of binding interaction and ADME properties of novel 5-(thiophen-2-yl)-1,3,4-oxadiazole-2-amine derivatives as anti-proliferative agents. Int J App Pharm. January 2023. Vol. 15(1). P: 141–6.
26- Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. March 2017. Vol. 7.
27- Niu P, Kang J, Tian X, Song L, Liu H, Wu J, et al. Synthesis of 2-amino-1,3,4-oxadiazoles and 2-Amino-1,3,4-thiadiazoles via sequential condensation and I2-mediated oxidative C-O/C-S bond formation. J Org Chem. January 2015. Vol. 80(2). P: 1018–24.
28- Nawghare BR, Gaikwad SV, Raheem A, Lokhande PD. Iodine catalyzed cascade synthesis of flavone derivatives from 2’-allyloxy-α,βdibromo chalcones. J Chil Chem Soc. March 2014. Vol. 59(1). P: 291–302.
29- Jabbar ZA, Mahdi MF, Abd Razik BM. Synthesis, Characterization, ADME Study and Anti-proliferative evaluation against MCF-7 breast cancer cell line of new analog of a 4-aminophenyl quinazolinone derivative. Al Mustansiriyah Journal of Pharmaceutical Sciences. April 2023. Vol. 23(4). P: 411-28.
30- Mahdi MF, Raauf AMR, Kadhim FAH. Design, Synthesis and Acute Anti-Inflammatory Evaluation of New Non-Steroidal Anti-Inflammatory Agents Having 4-Thiazolidinone Pharmacophore. J Nat Sci Res. 2015. Vol. 5(6). P: 21-9.
31- Kaplan A, Akalin Ciftci G, Kutlu HM. The apoptotic and genomic studies on A549 cell line induced by silver nitrate. Tumour Biol. April 2017. Vol. 39(4). P: 1-12.
32- Shi Y, Tang B, Yu PW, Tang B, Hao YX, Lei X, Luo HX, Zeng DZ. Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells. PLoS One. November 2012. Vol. 7(11). P:1-8.
33- Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, et al. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. Eur J Med Chem. July 2017. Vol. 138. P: 669–88.
34- Shaaban OG, Abd El Razik HA, A Shams El-Dine SED, Ashour FA, El-Tombary AA, Afifi OS, et al. Purines and triazolo[4,3-e]purines containing pyrazole moiety as potential anticancer and antioxidant agents. Future Med Chem. June 2018. Vol. 10(12). P: 1449–64.
35- Sebaugh JL. Guidelines for accurate EC50/IC50 estimation. Pharm Stat. March 2011. Vol. 10(2). P: 128–34.
36- Fishmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, et al. Structure-guided discovery of cyclin-dependent kinase inhibitors. Biopolymers. May 2008. Vol. 89(5). P: 372–9.
37- Jevtovic V, Alshammari N, Latif S, Alsukaibi AKD, Humaidi J, Alanazi TYA, et al. Synthesis, Crystal Structure, Theoretical Calculations, Antibacterial Activity, Electrochemical Behavior, and Molecular Docking of Ni(II) and Cu(II) Complexes with Pyridoxal-Semicarbazone. Molecules. October 2022. Vol. 27(19).
38- Shang ZH, Sun JN, Guo JS, Sun YY, Weng WZ, Zhang ZX, et al. Facile synthesis of 1,3,4-oxadiazoles via iodine promoted oxidative annulation of methyl-azaheteroarenes and hydrazides. Tetrahedron. February 2020. Vol. 76(6).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yousef Sabah Ali, Monther Faisal Mahdi, Basma Monjid Abd Razik, Talal Aburjai
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
